H.C. Wainwright reiterates Buy rating on Tango Therapeutics stock

H.C. Wainwright reiterated its Buy rating and $13 price target for Tango Therapeutics (TNGX) following the dosing of its first patient in a Phase 1/2 trial for TNG462, a combination therapy targeting MTAP-deleted and RAS mutant cancers, supported by promising preclinical data. This clinical advancement, alongside the initiation of another Phase 1/2 trial for TNG456, underpins analyst confidence, aligning with the stock's over 62% gain in the past six months. Financially, Tango reported a Q4 2024 net loss of $0.35 per share, largely in line with estimates, and ended 2024 with $257.9 million in cash, projected to fund operations into Q3 2026.

Analysis

H.C. Wainwright's reiteration of a Buy rating and $13.00 price target for Tango Therapeutics (TNGX) is anchored by the initiation of a pivotal Phase 1/2 clinical trial. This trial evaluates TNGX's TNG462 in combination with Revolution Medicines' RAS inhibitors for MTAP-deleted and RAS mutant cancers, a strategy supported by promising preclinical data showing enhanced antitumor activity. This clinical milestone, coupled with the start of a separate Phase 1/2 trial for TNG456 in solid tumors, demonstrates progress across the company's pipeline. Financially, Tango's Q4 2024 net loss of $0.35 per share was closely aligned with analyst estimates, and its year-end cash position of $257.9 million provides a sufficient runway to fund operations into the third quarter of 2026. This strong financial footing mitigates near-term dilution risk and allows focus on clinical execution. The stock's significant appreciation of over 62% in the past six months reflects growing market confidence, which is further validated by a strong bullish consensus among analysts.

Key Decisions for Investors

• Given the positive clinical developments and strong analyst support, investors may view the stock's recent momentum as fundamentally justified, warranting consideration to hold or add to positions.
• The primary catalysts for TNGX will be data readouts from its ongoing Phase 1/2 trials for TNG462 and TNG456; investors should closely monitor trial progress and any interim safety or efficacy announcements.
• While the company's cash runway into Q3 2026 provides a significant operational cushion, investors must recognize that the investment remains speculative and is highly dependent on successful clinical trial outcomes.